Description

Axsome Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and developing innovative treatments for central nervous system (CNS) disorders, primarily focusing on the United States market. Its pipeline includes AXS-05, a therapeutic candidate for major depressive disorder and treatment-resistant depression, which is also currently in Phase III clinical trials for Alzheimer's disease agitation and has completed Phase II studies for smoking cessation. The company is also advancing AXS-07, an experimental, rapidly absorbed, oral medication with a multi-mechanistic profile, which has successfully concluded two Phase III trials for the acute treatment of migraine. Another key asset is AXS-12, a selective and potent norepinephrine reuptake inhibitor, presently in Phase III development for narcolepsy. Furthermore, AXS-14, an investigational oral medicine, is undergoing Phase III trials for fibromyalgia. Axsome Therapeutics maintains a research collaboration with Duke University to further evaluate AXS-05 for smoking cessation. The company was founded in 2012 and is headquartered in New York, New York.